表皮生长因子受体靶向药物的研究现状

Research status of epidermal growth factor receptor targeting drugs

表皮生长因子受体(EGFR)在许多恶性肿瘤中过度表达,针对EGFR的靶向药物可以有效、高选择性地抑制EGFR活性,从而有效治疗多种恶性肿瘤。EGFR靶向药物目前主要包括小分子表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)、单克隆抗体(mAbs)以及抗体偶联药物(ADC)等。本文将就EGFR靶向药物的作用机制、药物分类和联合治疗做一综述。

Epidermal growth factor receptor(EGFR)is overexpressed in many malignant tumors,and targeted drugs against EGFR can effectively and selectively inhibit EGFR activity,thereby effectively treating a variety of malignant tumors.EGFR-targeted drugs include small molecule epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs),monoclonal antibodies(mAbs),and antibody-drug conjugate(ADC).This paper will review the mechanism of action,drug classification and combination therapy of EGFR-targeted drugs.